Harry J. Long, MD [clinicaltrials_resource:2a13cae2007368890c9f4275af09e8f7]
Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer [clinicaltrials:NCT00003945]Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus [clinicaltrials:NCT00033644]S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer [clinicaltrials:NCT00057928]Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer [clinicaltrials:NCT00276796]
overall official [clinicaltrials_vocabulary:overall-official]
Harry J. Long, MD [clinicaltrials_resource:2a13cae2007368890c9f4275af09e8f7]
Bio2RDF identifier
2a13cae2007368890c9f4275af09e8f7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2a13cae2007368890c9f4275af09e8f7
affiliation [clinicaltrials_vocabulary:affiliation]
last name [clinicaltrials_vocabulary:last-name]
Harry J. Long, MD
role [clinicaltrials_vocabulary:role]
Study Chair
identifier
clinicaltrials_resource:2a13cae2007368890c9f4275af09e8f7
title
Harry J. Long, MD
@en
type
label
Harry J. Long, MD [clinicaltrials_resource:2a13cae2007368890c9f4275af09e8f7]
@en